Cargando…
Pharmacokinetic and pharmacodynamic actions of clozapine-N-oxide, clozapine, and compound 21 in DREADD-based chemogenetics in mice
Muscarinic Designer Receptors Exclusively Activated by Designer Drugs (DREADD) gated by clozapine-N-oxide (CNO) allow selective G-protein cascade activation in genetically specified cell-types in vivo. Here we compare the pharmacokinetics, off-target effects and efficacy of CNO, clozapine (CLZ) and...
Autores principales: | Jendryka, Martin, Palchaudhuri, Monika, Ursu, Daniel, van der Veen, Bastiaan, Liss, Birgit, Kätzel, Dennis, Nissen, Wiebke, Pekcec, Anton |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6418145/ https://www.ncbi.nlm.nih.gov/pubmed/30872749 http://dx.doi.org/10.1038/s41598-019-41088-2 |
Ejemplares similares
-
Control of sustained attention and impulsivity by G(q)-protein signalling in parvalbumin interneurons of the anterior cingulate cortex
por: Jendryka, Martin M., et al.
Publicado: (2023) -
The DREADD agonist clozapine N-oxide (CNO) is reverse-metabolized to clozapine and produces clozapine-like interoceptive stimulus effects in rats and mice
por: Manvich, Daniel F., et al.
Publicado: (2018) -
Optimizing clozapine for chemogenetic neuromodulation of somatosensory cortex
por: Cho, Jongwook, et al.
Publicado: (2020) -
DREADD: A Chemogenetic GPCR Signaling Platform
por: Zhu, Hu, et al.
Publicado: (2014) -
The DREADDful Hurdles and Opportunities of the Chronic Chemogenetic Toolbox
por: Claes, Marie, et al.
Publicado: (2022)